Antares Pharma Reports Third Quarter 2017 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Antares Pharma (ATRS) PT Lowered to $5 at Jefferies
November 8, 2017 8:44 AM ESTJefferies lowered its price target on Antares Pharma (NASDAQ: ATRS) to $5.00 (from $6.00) while maintaining a Buy rating.
Analyst Anthony Petrone notes ATRS reported a solid 3Q17; however the focus remains squarely on XYOSTED and other pipeline developments.
... MoreAntares Pharma (ATRS) Reports In-Line Q3 EPS
November 7, 2017 7:03 AM ESTAntares Pharma (NASDAQ: ATRS) reported Q3 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $15.1 million versus the consensus estimate of $13.96 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
... More